



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Salvatore Albani

Application No.: 10/614,639

Filed: 7/7/2003

Title: T-Cell Capture: Methods for Isolation,
Quantification, Characterization and Modulation
of Antigen-Specific T Cells

Attorney Docket No.: AND-1001-DIV2

Group Art Unit:

1636

Examiner:

To Be Assigned

REQUEST FOR CORRECTION


Mail Stop: MISSING PARTS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Petitioner hereby requests a correction in the Filing Receipt of the above-referenced patent application. Enclosed is a copy of the Filing Receipt with the changes noted thereon.

Respectfully submitted,

July 7, 2004
Date


Daniel M. Chambers

Reg. No. 34561

Attorney for Applicant

Daniel M. Chambers
Biotechnology Law Group
658 Marsolan Avenue
Solana Beach, CA 92075
Telephone: 858-350-9690
Fax: 858-350-9691

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail postage prepaid in an envelope addressed to: MAIL STOP: MISSING PARTS, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date of Deposit: JULY 7, 2004

Typed Name: Daniel M. Chambers, A.C.

Signature: Daniel M. Chambers



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (C) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/614,639	07/07/2003	1636	375	AND-700-SIR1-DIV2 AND-1001-DIV2	38	1	1

CONFIRMATION NO. 8214

Daniel M. Chamber
Bio Technology Law Group
658 Marsolan Avenue
Solana Beach, CA 92075-1931



FILING RECEIPT



OC000000013051992

Date Mailed: 06/24/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Salvatore Albani, San Diego, CA;

→ DIV of 09/756,983 1/9/2001
which is a

Domestic Priority data as claimed by applicant

This application is a CIP of 09/421,506 10/19/1999 which is a CPA of 09/421,506 9-36-2003
which is a CON of and is a CIP of PCT/US99/24666 10/19/1999
which claims benefit of 60/105,018 10/20/1998

Foreign Applications

If Required, Foreign Filing License Granted: 06/23/2004

Projected Publication Date: To Be Determined - pending completion of Sequence Disclosures

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Devices comprising artificial antigen-presenting cells
Methods for Isolation, Quantification, Characterization and Modulation of Antigen-Specific T Cells

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).